Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis
Poor weight gain during first year of ART associated with increased mortality risk for children with HIV in resource-limited settings
European HIV response "falling behind" as Eastern European epidemic grows
Reduced physical function significantly increases mortality risk of middle-aged people living with HIV
Safer injecting practices would be better promoted by focusing on pleasure and practical concerns – not the risk of infection
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation
Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use
